ClinicalTrials.gg

Program

SCTB41

A development code. Also written as “SCTB41+SCTB39G” and “SCTB41+SCTB39-1”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lymphoma, Non-Hodgkin, led by Sinocelltech Group.

Furthest: phase 3, since Jun 16, 20266 company-led studies, 6 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinocelltech Group66 open or runningphase 3since Jun 16, 2026Sep 12, 2024Apr 30, 2027phase 2 · NCT06600022

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2024First study: phase 2 study in Advanced Malignant Solid TumoursFirst studyNCT06600022 · 441 planned · China
  2. May 11, 20262 phase 2 studiesNCT07594028, NCT07609251
  3. Jun 16, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07662395 · 410 planned · China
  4. Jun 18, 2026Phase 2 study in Advanced Malignant Solid TumorsNCT07665970 · 112 planned
  5. Sep 8, 2026Phase 2 study in Lymphoma, Non-HodgkinNCT07819188 · 90 planned · China

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in Advanced Malignant Solid TumoursNCT06600022
  2. Sep 30, 2028Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07819188
  3. Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07609251
  4. May 30, 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07594028

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07819188Lymphoma, Non-Hodgkin · China2Not yet recruitingSep 30, 202890
NCT07665970Advanced Malignant Solid Tumors2Not yet recruitingJun 30, 2029112
NCT07662395Carcinoma, Non-Small-Cell Lung · China3RecruitingJan 24, 2030410
NCT07609251Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingOct 202890
NCT07594028Advanced Malignant Solid Tumor2Not yet recruitingMay 30, 2029126
NCT06600022Advanced Malignant Solid Tumours · China2RecruitingApr 30, 2027441

How it is read

Names in the registry

  • “SCTB41”, 4 entries
  • “SCTB41+SCTB39G”, 1 entry
  • “SCTB41+SCTB39-1”, 1 entry

Codes read as this program: SCTB41.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.